Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Neumora Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 12.2M | $146M | $11.98 | Jun 13, 2024 | By ARCH Venture Fund X, L.P. |
Neumora Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 11.9M | $142M | $11.98 | Jun 13, 2024 | By ARCH Venture Fund X Overage, L.P. |
Beam Therapeutics Inc. | Director | Common Stock | 2.72M | $71.9M | $26.42 | Jun 6, 2023 | Indirect |
Neumora Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 4.13M | $49.5M | $11.98 | Jun 13, 2024 | By ARCH Venture Fund XII, L.P. |
Neumora Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 2.32M | $27.8M | $11.98 | Jun 13, 2024 | By ARCH Venture Fund VIII Overage, L.P. |
Scholar Rock Holding Corp | Director | Common Stock | 2.35M | $21.1M | $8.99 | Jun 27, 2024 | Indirect |
Neumora Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 1.39M | $16.6M | $11.98 | Jun 13, 2024 | By ARCH Venture Fund VII, L.P. |
Beam Therapeutics Inc. | Director | Common Stock | 26K | $687K | $26.42 | Jun 6, 2023 | Direct |
Neumora Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 47.7K | $572K | $11.98 | Jun 13, 2024 | Direct |
Beam Therapeutics Inc. | Director | Stock Option (Right to Buy) | 16.5K | $403K | $24.40 | Jun 6, 2023 | Direct |
Scholar Rock Holding Corp | Director | Common Stock | 18.8K | $169K | $8.99 | Jun 27, 2024 | Direct |
Boundless Bio, Inc. | Director, 10%+ Owner | Common Stock | 1.18M | Apr 2, 2024 | Indirect | ||
Gossamer Bio, Inc. | Director | Stock Option (Right to Buy) | 35K | Jun 8, 2023 | Direct | ||
Neumora Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 28.6K | Jun 13, 2024 | Direct | ||
Boundless Bio, Inc. | Director, 10%+ Owner | Stock Option | 26.4K | Mar 27, 2024 | Direct | ||
Unity Biotechnology, Inc. | Director | Stock Option (Right to Buy) | 25K | Jun 24, 2021 | Direct | ||
Scholar Rock Holding Corp | Director | Stock Option (Right to Buy) | 18K | Jun 27, 2024 | Direct | ||
Metacrine, Inc. | Director | Stock Option (right to buy) | 16.5K | May 24, 2021 | Direct | ||
Boundless Bio, Inc. | Director, 10%+ Owner | Series A Convertible Preferred Stock | 0 | Apr 2, 2024 | Indirect | ||
Boundless Bio, Inc. | Director, 10%+ Owner | Series B Convertible Preferred Stock | 0 | Apr 2, 2024 | Indirect | ||
Boundless Bio, Inc. | Director, 10%+ Owner | Series C Convertible Preferred Stock | 0 | Apr 2, 2024 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SRRK | Scholar Rock Holding Corp | Jun 27, 2024 | 2 | $0 | 4 | Jul 1, 2024 | Director |
NMRA | Neumora Therapeutics, Inc. | Jun 13, 2024 | 2 | $0 | 4 | Jun 14, 2024 | Director, 10%+ Owner |
BOLD | Boundless Bio, Inc. | Apr 2, 2024 | 12 | $3.2M | 4 | Apr 4, 2024 | Director, 10%+ Owner |
BOLD | Boundless Bio, Inc. | Mar 27, 2024 | 1 | $0 | 4 | Mar 29, 2024 | Director, 10%+ Owner |
BOLD | Boundless Bio, Inc. | Mar 27, 2024 | 0 | $0 | 3 | Mar 27, 2024 | Director, 10%+ Owner |
SRRK | Scholar Rock Holding Corp | Dec 21, 2023 | 2 | $0 | 4 | Dec 26, 2023 | Director |
NMRA | Neumora Therapeutics, Inc. | Dec 8, 2023 | 3 | $0 | 4 | Dec 12, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Nov 13, 2023 | 2 | $412K | 4 | Nov 15, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Nov 8, 2023 | 5 | $1.54M | 4 | Nov 13, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Nov 3, 2023 | 3 | $1.1M | 4 | Nov 7, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Sep 28, 2023 | 3 | $1.05M | 4 | Sep 29, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Sep 26, 2023 | 2 | $700K | 4 | Sep 27, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Sep 22, 2023 | 3 | $1.13M | 4 | Sep 25, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Sep 19, 2023 | 13 | $25.5M | 4 | Sep 20, 2023 | Director, 10%+ Owner |
NMRA | Neumora Therapeutics, Inc. | Sep 14, 2023 | 1 | $0 | 4 | Sep 18, 2023 | Director |
NMRA | Neumora Therapeutics, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 14, 2023 | Director, 10%+ Owner |
SRRK | Scholar Rock Holding Corp | Jun 21, 2023 | 1 | $0 | 4 | Jun 23, 2023 | Director |
GOSS | Gossamer Bio, Inc. | Jun 8, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
BEAM | Beam Therapeutics Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director |
BEAM | Beam Therapeutics Inc. | Sep 1, 2022 | 1 | $0 | 4 | Sep 2, 2022 | Director |
GOSS | Gossamer Bio, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jul 15, 2022 | Director |
SRRK | Scholar Rock Holding Corp | May 26, 2022 | 1 | $0 | 4 | May 27, 2022 | Director |
BEAM | Beam Therapeutics Inc. | Jun 30, 2021 | 3 | $0 | 4 | Jul 2, 2021 | Director |
BEAM | Beam Therapeutics Inc. | Jun 25, 2021 | 6 | $0 | 4 | Jun 29, 2021 | Director |
UBX | Unity Biotechnology, Inc. | Jun 24, 2021 | 1 | $0 | 4 | Jun 28, 2021 | Director |
BEAM | Beam Therapeutics Inc. | Jun 10, 2021 | 1 | $0 | 4 | Jun 14, 2021 | Director |
GOSS | Gossamer Bio, Inc. | Jun 9, 2021 | 1 | $0 | 4 | Jun 10, 2021 | Director |
SRRK | Scholar Rock Holding Corp | May 27, 2021 | 1 | $0 | 4 | Jun 1, 2021 | Director |
MTCR | Metacrine, Inc. | May 24, 2021 | 1 | $0 | 4 | May 25, 2021 | Director |